showing complete loss of membrane staining, whereas 93% of IDC retained some level of expression. In IDC reactivity was not related to tumour grade but there was a significant association between reduced membrane levels of E-cadherin and the presence of lymph node metastasis, and a highly significant correlation between the presence of cytoplasmic E-cadherin and metastasis. A significant relationship was also demonstrated between reduced E-cadherin reactivity and expression of EGFR. These findings emphasise the complexity of control of E-cadherin in breast carcinomas and provide evidence of a link between membrane signalling pathways and modulation of E-cadherin expression.
Tumour cell invasion and metastasis is a multistep process requiring complex alterations in adhesive interactions. Detachment of tumour cells from the primary lesion is considered to be an important early step in the metastatic process (Coman, 1947) . Adhesion is mediated by several families of cell adhesion molecules, including integrins (Hynes, 1992) and members of the immunoglobulin family (Springer, 1990) . However, in epithelial cells E-cadherin (also known as L-CAM, uvomorulin and Arc-1) plays a critical role in initiating and maintaining cell-cell contacts (Takeichi, 1988) .
E-cadherin is a member of the growing family of calciumdependent cadherin adhesion molecules (Kemler, 1992) . Ecadherin molecules are located within adherens junctions and are transmembrane structures mediating homotypic interactions between one or more of the extracellular cadherin repeats. The cytoplasmic region interacts with a group of proteins named the catenins, which in turn are connected to the actin microfilament network (Kemler, 1993) .
That loss of E-cadherin function may be involved in tumour cell invasion has been demonstrated by an inverse relationship between expression of E-cadherin and invasive behaviour in some tumour cell lines , and this tumour-suppressor function has been supported by inhibition of tumour cell invasion following transfection of cells with E-cadherin cDNA . A more complex relationship has been observed between unstable or aberrant expression of cadherins and metastatic potential of tumour cells (Hashimoto et al., 1989; Mareel et al., 1991) . While a clear role for E-cadherin in preventing tumour cell invasion has emerged from these in vitro studies, the relationship between E-cadherin expression in primary tumours and other prognostic parameters is inconsistent. In breast carcinomas, some studies have revealed a significant correlation between reduced E-cadherin expression and the presence of lymph node metastasis (Oka et al., 1993) , and with histological grade (Moll et al., 1993) . However, other studies have shown no such correlation (Lipponen et al., 1994) .
Evidence of the biological importance of E-cadherin in breast carcinomas is illustrated by the studies of D'Souza et al. (1994) , who found that overexpression of erbB-2 in a nontumorigenic mammary epithelial cell line leads to downregulation of E-cadherin gene transcription. The erbB-2 proto-oncogene is a transmembrane tyrosine kinase receptor that shows homology to epidermal growth factor receptor (EGFR), and overexpression of this gene in breast carcinomas is associated with a rapid growth rate and a poor prognosis (Berger et al., 1988; Walker et al., 1989) . That it also affects E-cadherin gene transcription suggests that this may be a mechanism whereby erbB-2 can affect the metastatic process.
A further relationship between the regulation of cell growth and E-cadherin expression is demonstrated by the culture of MCF-7 tumour cells in the presence of the antioestrogenic agent tamoxifen (Bracke et al., 1994) . This agent, which inhibits tumour cell growth, has been shown to restore E-cadherin-mediated adhesive function to these cells. Control of E-cadherin function can also be modulated by EGF. Kemler (1993) showed that in vitro activation of the EGFR with subsequent phosphorylation of its cytoplasmic domain is associated with dissociation of the E-cadherin/catenin complex from the cytoskeleton. Studies have shown that expression of EGFR by breast carcinomas is related to a poor prognosis (Sainsbury et al., 1987) and Kemler's (1993) findings suggest that this may in part be mediated by altered E-cadherin function. However, in contrast to this, Oka et al. (1993) found a significant association between EGFR expression in primary breast carcinomas and retained Ecadherin reactivity.
Given this evidence of a relationship between E-cadherin function and growth control, as well as invasive behaviour in vitro, it is important to examine whether these associations are maintained in an in vivo situation. The aim of this study, therefore, was to examine the expression of E-cadherin in primary breast carcinomas and to relate this to clinicopathological parameters including tumour grade and lymph node status, and also to determine the relationship between E- (Elston et al., 1991) . Information on lymph node status was known for 154 cases.
Immunohistochemistry
For detection of E-cadherin, 5 pm cryostat sections were cut onto silane-coated slides and allowed to air dry for 30 min. Sections were then fixed in acetone for 10 min at 4°C. The sections were incubated in normal rabbit serum (Sigma) for 10 min to block non-specific binding and then incubated overnight at 4°C with the mouse monoclonal anti-E-cadherin antibody (Euro-Path Ltd) at a dilution of 1:50 in Trisbuffered saline with 0.1% bovine serum albumin (BSA). A standard streptavidin -biotin complex (ABC) indirect immunoperoxidase technique was used to localise the bound antibody, which involved sequential incubation with biotinylated rabbit anti-mouse IgG at a dilution of 1:200 and streptavidin combined in vitro with biotinylated horseradish peroxidase (Dako), the reaction product being visualised using diaminobenzidine (DAB) hydrochloride.
Known positive cases (benign breast tissue) and negative controls (omission of the primary antibody) were included in each run and were shown to be positive and negative respectively. Normal breast epithelial elements in the tumour sections were used as internal positive controls.
Frozen tissue was also used for detection of oestrogen receptor (ER), using the ERICA Kit (Abbott), and for detection of EGFR, using EGFR 1 monoclonal antibody (Amersham) at a dilution of 1:50. Formalin-fixed, paraffinembedded tissue was used for detection of c-erbB-2, using the monoclonal antibody NCL-CBI1 (Novocastra) at a dilution of 1:100, and for localisation of pS2 protein using the monoclonal antibody Histo CIS pS2 undiluted. In each case a standard ABC technique was used as described above. Known positive cases and negative controls were included in each run.
Evaluation
The extent and distribution of reactivity for E-cadherin was recorded in each case using a semi-quantitive scoring system. Staining was classed as 4 if >80% of the tumour showed reactivity, 3 if 50-80% was positive, 2 if 20-50% of the tumour showed staining, 1 for patchy, focal reactivity and 0 if there was no evidence of staining. This system was applied to each tumour to determine the extent of reactivity for each of the two patterns of localisation observed, membrane and cytoplasmic.
Tumours (Figure 2 ). In addition to membrane staining, in many of the tumours a variable proportion of cells exhibited cytoplasmic reactivity for E-cadherin, in some cases this being the predominant pattern observed (Figure 3 ). Of the 13 cases of tubular carcinoma examined, one showed no reactivity for E-cadherin, either membrane or cytoplasmic, despite a normal distribution of E-cadherin in adjacent nonmalignant ducts. The other tubular carcinomas displayed variable levels of membrane and cytoplasmic staining in a pattern similar to that of the IDC.
In marked contrast to the IDC, none of the 12 cases of infiltrating lobular carcinomas included in the study showed any evidence of membrane reactivity for E-cadherin ( Figure  4) , although in three cases there was weak cytoplasmic reactivity in a small proportion of the tumour cells. Three of the cases also contained areas of lobular carcinoma in situ (LCIS), which were similarly negative for E-cadherin.
The six cases of pure DCIS, including one case of comedo- (Table I ). The absence of reactivity observed in nine IDC was also not related to tumour grade. The 13 tubular carcinomas, all by definition grade I, displayed variable levels and patterns of staining, some having predominantly cytoplasmic reactivity, others with near normal levels of membrane staining.
When the pattern of E-cadherin expression was correlated with the lymph node status of the patient, both for the IDC alone and the IDC together with the tubular carcinomas, there was a significant association between reduced membrane reactivity and the presence of lymph node metastasis (0.005>P>0.001). Interestingly, a highly significant association was demonstrated between the presence of cytoplasmic reactivity for E-cadherin in the tumour cells and Figure 2 Moderately differentiated infiltrating ductal carcinoma displaying membrane reactivity for E-cadherin on the majority of tumour cells. lymph node metastasis (P<0.001) (Table I) , including two unusual cases of tubular carcinoma which showed extensive cytoplasmic reactivity. The lack of membrane E-cadherin in the infiltrating lobular carcinomas did not relate to lymph node metastasis, with eight cases being lymph node-positive and two being lymph node-negative. Similarly, there was no relationship to the presence of cytoplasmic reactivity. E-cadherin reactivity in relation to other markers For the infiltrating ductal carcinomas, no significant correlation was observed between the extent and pattern of E-cadherin reactivity and ER status, c-erbB-2 expression or pS2 expression (Table I) . However, a statistically significant relationship was evident between the presence of cytoplasmic reactivity for E-cadherin in the tumour cells and EGFR positivity (0.01>P>0.005). This relationship could also be demonstrated at the cellular level, with colocalisation of the cytoplasmic E-cadherin and EGFR within tumour groups. No such relationship was seen for the presence of membrane reactivity and EGFR positivity. These relationships were maintained when the tubular carcinomas were included in this group.
The groups of infiltrating lobular carcinoma and DCIS were too small for statistical analysis. However, no clear relationship with any of the factors was evident.
Discussion
The process of tumour progression, invasion and metastasis is a complex cascade of events (Hart et al., 1989) , which involves escape from normal growth control mechanisms, invasion of surrounding stroma and release of neoplastic cells from the primary tumour with subsequent establishment and growth at a distant site. Many of these processes imply altered adhesive function of the neoplastic cells, and in epithelial tumours, altered E-cadherin function has been shown to play a critical role in allowing release of neoplastic cells from a normal cohesive structure. However, there is recent evidence that different stages of tumour development may be closely linked, with mitogenic signals also affecting cell adhesion (D'Souza et al., 1994) , and this study has evaluated whether these relationships are maintained in vivo.
A number of studies have established an inverse correlation between E-cadherin expression and tumour differentiation (Schipper et al., 1991; Kinsella et al., 1993) . In infiltrating ductal carcinomas (IDC) of the breast, the relationship of E-cadherin expression to clinicopathological (Pignatelli et al., 1994) , although the significance of this distribution has not been addressed. We demonstrated a highly significant association between tumour cytoplasmic reactivity for E-cadherin and the presence of lymph node metastasis. There are a number of possible explanations for this finding. One is that the cytoplasmic reactivity indicates a reversible change in Ecadherin expression by the cell in response to the local environment. It has been demonstrated that E-cadherin expression can easily be altered in vitro in response to the culture environment and that highly metastatic ovarian tumour cells have unstable E-cadherin expression (Hashimoto et al., 1989) . Such a temporal disruption of E-cadherin-mediated adhesion would allow tumour cell detachment, while re-expression could favour colonisation at a distant site. In support of this, there are reports of increased E-cadherin expression in metastatic lesions compared with their primary tumour (Mayer et al., 1993) . Alternatively, such aberrant E-cadherin localisation may be the result of abnormal catenin expression. Incorporation of E-cadherin into stable cell-cell contacts is modulated by the cytoplasmic proteins, a-, f-and y-catenin (Hirano et al., 1992; Hinck et al., 1994) . Thus, loss of one or more of the catenin proteins may be expected to result in weak association of E-cadherin to the cytoskeleton, distribution diffusely within the cytoplasm and loss of adhesive function. Interestingly, altered expression of y-catenin (plakoglobin) has recently been reported in human breast cancer cells (Sommers et al., 1994) . It would be of interest to examine the association of cytoplasmic reactivity for E-cadherin with catenin gene expression.
There is increasing evidence that E-cadherin function may be modulated by growth factor activity. Hoschuetzky et al. (1994) have demonstrated the physical association of EGFR with E-cadherin via fl-catenin, while Shiozaki et al. (1995) have shown that phosphorylation of EGFR leads to dissociation of E-cadherin/catenin complexes from the cytoskeleton. In keeping with this, our study demonstrates a significant correlation between the expression of EGFR by tumour cells and the presence of cytoplasmic reactivity for Ecadherin. This may illustrate one mechanism whereby local environmental influences could modulate both tumour cell growth and invasive behaviour. Oka et al. (1993) have reported an association between EGFR positivity and retained E-cadherin expression by tumours, although the localisation of this reactivity was not reported.
Further evidence linking cadherins to signalling pathways is illustrated by the down-regulation of E-cadherin transcription in response to overexpression of the tyrosine kinase receptor erbB-2 in a non-tumorigenic human mammary epithelial cell line (D'Souza et al., 1994) . Our study showed no relationship between c-erbB-2 expression and E-cadherin reactivity, demonstrating perhaps the complexity of factors involved in tumour progression.
Possession of ER and reactivity for the oestrogenregulated protein, pS2, are generally indicative of tumours with a good prognosis (Foekens et al., 1990) . Transfection of a mouse mammary adenocarcinoma cell line with pS2 cDNA has been shown to alter cell phenotype, giving the previously cohesive cell colonies a more dispersed structure (Williams et al., 1995) and suggesting altered adhesive interactions, although our study does not support a direct effect on Ecadherin expression. In contrast to Lipponen et al. (1994) , we found no correlation between E-cadherin expression and ER status.
While E-cadherin reactivity was maintained in 93% of infiltrating ductal carcinomas, none of the infiltrating lobular carcinomas or LCIS showed evidence of membrane Ecadherin. These findings are in keeping with those of other workers (Moll et al., 1993; Lipponen et al., 1994) and suggest distinct modes of invasion in these two cancer types. Interestingly, a similar pattern of staining is seen in diffusetype gastric carcinomas, which are also characterised by lack of glandular differentiation and single, non-polarised cells infiltrating stroma (Mayer et al., 1993) . Furthermore, mutations in the E-cadherin gene have been discovered in this form of gastric carcinoma (Becker et al., 1994) . In infiltrating lobular carcinoma of breast also, loss of mRNA for E-cadherin has been demonstrated (Rasbridge et al., 1995) , and in some cases gene mutations have been identified (Kanai et al., 1994; Berx et al., 1995) .
In conclusion, the role of E-cadherin in breast tumour progression appears increasingly complex. Whereas in ILC loss of E-cadherin appears to be an early event in tumour development, in IDC altered E-cadherin expression appears to be more directly related to the metastatic process. The association of cytoplasmic E-cadherin with lymph node 1241 metastasis suggests a sophisticated control over cell-cell adhesion possibly in response to local growth factors such as EGF. This link between E-adherin expression and signalling pathways may be an important stage in understanding tumour progression and examination of the dynamic interaction between these two factors, in particular the control of catenin expression in relation to this, merits further study.
